Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine DOI Creative Commons

Lucrezia Mencarelli,

Laura Moi, Natacha Dewarrat

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1335 - 1335

Published: Aug. 7, 2023

During one of the worst global health crises, millions people were vaccinated against SARS-CoV-2. In rare cases, new onset systemic inflammatory diseases reported with temporal coincidence to vaccination. We describe a case severe Eosinophilic Granulomatosis Polyangiitis (EGPA) in young asthmatic woman, occurring after second dose mRNA-1273 vaccine. She presented multisystem EGPA cardiac and central nervous system involvement, complicated by secondary immune thrombocytopenia (ITP). review cases coinciding SARS-CoV-2 mRNA All potentially vaccine-related so far occurred within 14 days from immunization. is very an incidence 1:1,000,000 inhabitants, number post-vaccination lies expected rate for period. While we cannot prove causal relationship between vaccine onset, stimulation intriguing, disease almost always adults asthma and/or chronic rhinosinusitis driven aberrant Th2 lymphocyte activation hypereosinophilia; nevertheless, (IMIDs) emerging context vaccination remain benefits preventing COVID presentations vaccines unquestionable.

Language: Английский

New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine DOI Creative Commons
Emanuele Nappi, Maria De Santis, Giovanni Paoletti

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 716 - 716

Published: May 3, 2022

Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic immune-mediated diseases (IMDs). There reports suggesting that may be able to trigger de-novo or exacerbate pre-existing IMDs predisposed individuals. Eosinophilic granulomatosis polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation various tissues. We describe the case of 63-year-old man who experienced cardiac, pulmonary, neurological involvement one day after administration booster dose anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis EGPA was made patient treated high-dose steroids cyclophosphamide, good clinical response. Interestingly, our had significant worsening his asthma six months earlier, just first two shots ChAdOx1 vaccine. It impossible know whether would have developed following natural SARS-CoV-2 infection at some point life regardless infectious stimuli. Nevertheless, report suggest caution should paid during additional doses an increase IMD severity persisted over time previous shots.

Language: Английский

Citations

32
Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review DOI Creative Commons
Eva Baier,

Ulrike Olgemöller,

Lorenz Biggemann

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 653 - 653

Published: April 21, 2022

As the coronavirus disease 2019 (COVID-19) pandemic is ongoing, and new variants of severe acute respiratory syndrome type 2 (SARS-CoV-2) are emerging, vaccines needed to protect individuals at high risk complications potentially control outbreaks by herd immunity. After SARS-CoV-2 vaccination, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) presenting with a pulmonary hemorrhage has been described. Previous studies suggested that monocytes upregulate major histocompatibility complex (MHC) II cell surface receptor human leukocyte antigen (HLA-DR) molecules in granulomatosis polyangiitis (GPA) patients proteinase 3 (PR3)- myeloperoxidase (MPO)-ANCA seropositivity. Here, we present case new-onset AAV after booster vaccination Pfizer-BioNTech mRNA vaccine. Moreover, provide evidence majority express HLA-DR vaccination. It possible enhanced immune response presence HLA-DR+ could be responsible for triggering production observed MPO- PR3-ANCA autoantibodies. Additionally, conducted systematic review de novo describing their clinical manifestations temporal association ANCA subtype, treatment regimens. In light hundred million being vaccinated worldwide, potential causal may result considerable subset cases complications.

Language: Английский

Citations

30
Eosinophils and COVID‐19: Insights into immune complexity and vaccine safety DOI Creative Commons

W. Sahli,

Joana Vitte, Benoît Desnues

et al.

Clinical and Translational Allergy, Journal Year: 2025, Volume and Issue: 15(3)

Published: March 1, 2025

Abstract Background COVID‐19 exhibits a variety of symptoms and may lead to multi‐organ failure death. This clinical complexity is exacerbated by significant immune dysregulation affecting nearly all cells the innate adaptive system. Granulocytes, including eosinophils, are affected SARS‐CoV‐2. Objectives Eosinophil responses remain poorly understood despite early recognition eosinopenia as hallmark feature severity. Results The heterogeneous nature eosinophil categorizes them dual‐function with contradictory effects. activation can suppress virus‐induced inflammation releasing type 2 cytokines like IL‐13 granular proteins antiviral action such eosinophil‐derived neurotoxins cationic protein, also acting antigen‐presenting cells. In contrast, accumulation in lungs induce tissue damage triggered or hormones IFN‐γ leptin. Additionally, they affect functions interacting T through direct formation membrane complexes soluble mediator action. Individuals allergic disorders who have elevated levels eosinophils tissues blood, asthma, do not appear be at an increased risk developing severe following SARS‐CoV‐2 infection. However, vaccine appears associated complications eosinophilic infiltrate‐induced immunopathogenicity, which mitigated corticosteroid, anti‐histamines anti‐IL‐5 therapy avoided modifying adjuvants excipients. Conclusion review highlights importance contributes better understanding their role during natural infection vaccination.

Language: Английский

Citations

1
New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review DOI Creative Commons
Arvind Nune,

Victor Durkowski,

S. Sujitha Pillay

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1571 - 1571

Published: Oct. 8, 2023

A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated demographics, management, and prognosis new R-IMIDs in adults SARS-CoV-2 vaccinations. literature search Medline, Embase, Google Scholar, LitCovid, Cochrane was conducted. We included any English-language study that reported R-IMID post-COVID-19 vaccination. total 271 cases were from 39 countries between January 2021 May 2023. The mean age patients 56 (range 18-90), most females (170, 62.5%). Most (153, 56.5%) received Pfizer BioNTech vaccine. Nearly 50% developed after second dose Vasculitis prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%). duration vaccine's 'trigger' 11 days. (220, 81.2%) corticosteroids; however, 42% (115) DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab. Complete remission achieved 75 (27.7%), 137 (50.6%) improved treatment. Two died due to myositis. This SR highlights vaccines may trigger R-IMID; further epidemiology studies are required.

Language: Английский

Citations

16
mRNA vaccines: A novel weapon to control infectious diseases DOI Creative Commons

Yuying Tian,

Zhuoya Deng,

Penghui Yang

et al.

Frontiers in Microbiology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 4, 2022

Infectious diseases have always threatened human life, but with the development of vaccines, effective strategies for preventing and controlling these become available. The global outbreak COVID-19 ushered in advent mRNA vaccine technologies, which quickly led to introduction vaccines against SARS-CoV-2. success this approach has stimulated research into use fight other emerging as well remerging infectious diseases. This review examines constructive delivery systems used provides an overview current clinical trials those prevention underlying mechanisms are also discussed, including double-edged sword innate immune response. Finally, challenges potential considered.

Language: Английский

Citations

20
New-onset severe eosinophilic granulomatosis with polyangiitis following the third dose of mRNA COVID-19 vaccine: A case report DOI Creative Commons

Salah Mahdi,

Anwar I. Joudeh,

Krishnamoorthy Sundara Raman

et al.

Modern Rheumatology Case Reports, Journal Year: 2023, Volume and Issue: 8(1), P. 153 - 158

Published: July 25, 2023

ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a complex multifactorial disease that results in multisystemic inflammation of the small- and medium-sized arteries. The exact pathogenesis this syndrome poorly understood, but it postulated to result from combination eosinophilic dysfunction, genetic predisposition, development autoantibodies after exposure an unknown stimulus. We describe case new-onset EGPA following third dose Pfizer-BioNTech mRNA vaccine infection-naive middle-aged man background history allergic respiratory symptoms. patient developed acute onset mononeuritis multiplex, pauci-immune glomerulonephritis, leucocytoclastic vasculitis 10 days receiving booster dose. His laboratory markers including eosinophil count, antineutrophil cytoplasmic antibodies, renal function tests improved markedly initiation pulse steroid therapy rituximab infusion. However, his peripheral muscle weakness neuropathic pain did not respond initial later intravenous cyclophosphamide immunoglobulin. To best our knowledge, fourth report post-coronavirus 2019 vaccination precipitation EGPA. All reported cases were patients previous manifestations who received mRNA-based coronavirus vaccines, all multiplex at presentation. Despite few post-vaccination autoimmune phenomena, temporal association between administration does indicate causality, given mass programmes employed. novel use platform delivery necessitates vigilant monitoring by scientific committee.

Language: Английский

Citations

9
COVID-19 vaccination as a rare potential etiology for cause of death after medicolegal autopsy. A Finnish nationwide study. DOI Creative Commons
Lasse Pakanen, Tuomo Nieminen, Paula Kuvaja

et al.

Vaccine X, Journal Year: 2025, Volume and Issue: unknown, P. 100645 - 100645

Published: April 1, 2025

Language: Английский

Citations

0
Eosinophilic fasciitis following SARS-CoV-2 vaccination DOI Creative Commons

Victoria Lobo Antuña,

Francesc Puchades Gimeno,

Jorge Magdaleno Tapial

et al.

JAAD Case Reports, Journal Year: 2023, Volume and Issue: 36, P. 11 - 14

Published: March 21, 2023

Language: Английский

Citations

8
New insights of antineutrophil cytoplasmic antibody-associated vasculitis from the perspective of COVID-19 vaccination DOI Creative Commons
Yang Yang,

Yi Xiong,

Gaosi Xu

et al.

Clinical & Experimental Immunology, Journal Year: 2023, Volume and Issue: 213(3), P. 301 - 309

Published: April 19, 2023

The occurrence of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) has been reported since the coronavirus disease 2019 (COVID-19) vaccination, but whether there is a causal relationship or coincidence remains to be verified. We combined term COVID-19 vaccination with each word AAV search for case reports and series published in PubMed, EMBASE, Web Science databases before 13 March 2023. A total 56 patients who developed after were identified from 44 research centers. Of subjects, 43 (76.7%) vaccinated mRNA vaccine, followed by adenovirus vaccine (14.3%) inactivated (9.0%) (P = 0.015). Compared relapsed AAV, new-onset had at least two other diseases previously < 0.001). Twenty-five (44.6%) presented symptoms first injection, medium onset time was 12 (1-77) days, while Twenty-eight (50.0%) second dose, their period 14 (1-60) days. Forty-four (78.5%) achieved remission immunosuppressive agents, plasma exchange, hemodialysis. One (1.8%) patient died progressive respiratory failure nine (16.1%) did not recover, leaving five permanently dependent on Pathogenic ANCA may activated enhanced immune response epitope spreading induced especially genetically susceptible populations.

Language: Английский

Citations

6
Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report DOI Creative Commons

Ayako Makiyama,

Yoshiyuki Abe,

Hoshiko Furusawa

et al.

Modern Rheumatology Case Reports, Journal Year: 2023, Volume and Issue: 8(1), P. 125 - 132

Published: June 15, 2023

ABSTRACT In response to the coronavirus disease 2019 pandemic, vaccine was rapidly developed and effectiveness of has been established. However, various adverse effects have reported, including development autoimmune diseases. We report a case new-onset polyarteritis nodosa in 32-year-old male following vaccination. The patient limb pain, fever, pulmonary embolism, multiple subcutaneous nodules, haematomas. Skin biopsy revealed necrotising inflammation accompanied by fibrinoid necrosis high inflammatory cell infiltration walls medium small arteries. symptoms resolved corticosteroid treatment. Although it is difficult prove relationship between nodosa, similar cases reported further reports analyses are therefore necessary.

Language: Английский

Citations

6